Skip to content
2000
Volume 2, Issue 1
  • ISSN: 1389-2002
  • E-ISSN: 1875-5453

Abstract

There is usually considerable variability in anticancer drug plasma levels when delivered at high doses requiring stem-cell support. Given their narrow therapeutic windows and wide interpatient pharmacokinetic variability, drug monitoring and pharmacokinetic-directed dosing represent an attractive strategy in this setting. A major previous requirement to successful application of therapeutic drug monitoring is identification of a significant and clinically meaningful pharmacodynamic correlation between a pharmacokinetic parameter and a toxic or therapeutic outcome, or preferably, both. In this review, we will analyze the current knowledge of identified pharmacodynamic correlations in high-dose chemotherapy. We will summarize the observations from other authors and our own, on drugs employed at high doses, such as cyclophosphamide, melphalan, busulfan, carmustine, paclitaxel, or docetaxel.

Loading

Article metrics loading...

/content/journals/cdm/10.2174/1389200013338720
2001-03-01
2025-05-25
Loading full text...

Full text loading...

/content/journals/cdm/10.2174/1389200013338720
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test